Overview

Sevelamer Hydrochloride in Peritoneal Dialysis Patients

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
0
Participant gender:
All
Summary
To test the hypothesis that second-line fixed low-dose sevelamer hydrochloride therapy is as effective as first-line high-dose sevelamer hydrochloride therapy in limiting the progression of cardiovascular calcification.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
The University of Hong Kong
Treatments:
Sevelamer
Criteria
Inclusion Criteria:

- ESRD patients receiving long-term peritoneal dialysis treatment with hyperphosphatemia
currently receiving aluminum-based phosphorus binders or whose phosphorus control
remains suboptimal with calcium-based binders only

- Patients who cannot afford to self-pay sevelamer hydrochloride.

- Patients who provided informed consent for the study

Exclusion Criteria:

- Patients with underlying active malignancy

- Patients with cyanotic congenital heart disease

- Patients with poor general condition

- Patients with plan for living related kidney transplant within coming 1 year

- Female patients with pregnancy